In the study of Arai et al. in which seven FGFR2–AHCYL1-positive and two FGFR2–BICC1-positive intrahepatic cholangiocarcinomas were identified, no significant differences in term of prognosis between fusion-positive and -negative patients were observed [32]. This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.